newsfilter
← Latest News
GlobeNewswire·

Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update

Early evidence of disease control was observed in the ongoing Phase 1 ACESOT-1051 trial, with three patients achieving stable disease in the 70 mg and 100 mg cohorts treated with the WEE1 inhibitor, APR-1051 $16.5